How Real World Evidence Continues to Shape the Late Phase Research Landscape

Life Sciences, Pharmaceutical, Drug Safety, Commercialization & HEOR,
  • Thursday, May 24, 2018

A Strategic, Technology-Driven Approach

Real world evidence has been a cornerstone of late phase research, providing stakeholders with answers on a product’s long-term safety, on which therapies are most effective in a real world setting, or on which treatment protocol is optimal. As technology and data availability advance, the way those questions are answered can become more efficient and targeted. Identifying and deploying a targeted data strategy can be an effective way to meet the goals and objectives of a product or study.

Opportunities are beginning to abound for the application of technology driven solutions to meet those late phase research objectives. Creating a comprehensive real world evidence strategy demands a focus on organizing and synthesizing the many real world data asset options that are available to life sciences companies. A fit-for-purpose real world evidence technology platform can serve as the foundation upon which to deliver maximum value from the aggregation of real world data sources. With big data solutions advancing to the forefront of the healthcare ecosystem, having access to a technology platform capable of generating a continuum of insights is paramount.


Bill Row, MBA, MS, Divisional Principal, Real World Evidence, ICON

Bill has over 17 years of experience in study design and execution. He is a recognised leader in the design, operational strategy, and commercial applications of real world evidence late phase studies for both pharma companies and CROs. His has held leadership roles in clinical operations, project management, and strategy/innovation.

Message Presenter

Bruce Capobianco, Sr. Director, RWE Technology, ICON

Bruce has over 20 years of experience in business technology and digital transformations. He has a proven track record leveraging technology as a facilitator for new innovative business capabilities. He is a sought after leader in the design and implementation of SaaS based, “Big Data” platforms. He has held various leadership roles in development, infrastructure, architecture and innovation teams across several distinct verticals.

Message Presenter

Holly Watts, Project Director, Real World Evidence, ICON

Holly has over 25 years of research experience including clinical and outcomes research in academic, CRO and clinical settings, and focused for 16 years in the Late Phase/Observational/HEOR environment. She has implemented a variety of study designs and scopes, ranging from large disease registries to specialized HEOR chart reviews and providing training and consultation in operational and strategic late phase data management issues.

Message Presenter

Who Should Attend?

Pharma, biotech and medical device professionals working in the areas of:

  • Real World Evidence
  • Market Access
  • Pricing and Contracting
  • Technology/RWE IT
  • Epidemiology
  • Health Outcomes and Observational Research (HEOR)

What You Will Learn

Attendees will gain valuable insights on:

  • The increase in availability of big data from primary and secondary sources and how it is shifting the research landscape
  • The strategic initiatives needed to identify which datasets can answer your research objectives and how to bring them together into one platform
  • The development of a fit-for-purpose real world evidence technology platform to maximize value from your data assets
  • Applying these tactics to an innovative use case

Xtalks Partner


ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, and to government. The company specialises in the strategic development, management and analysis of programs that support clinical development.  ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

Through its fully integrated Commercialisation & Outcomes services, ICON delivers resources and expertise to identify, generate, synthesize and communicate treatment safety and value, to help regulators, payers, providers and patients make informed health decisions.

With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,250 employees. For further information please visit Follow @iconplc on Twitter.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account